Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial
Authors:
- Gilberto FilaciGFGilberto Filaci
- Daniela FenoglioDFDaniela Fenoglio
- Franco NolèFNFranco Nolè
- Elisa ZanardiEZElisa Zanardi
- Laura TomaselloLTLaura Tomasello
- Massimo AgliettaMAMassimo Aglietta
- Gianluca Del ConteGCGianluca Del Conte
- Joan CarlesJCJoan Carles
- Rafael Morales-BarreraRMRafael Morales-Barrera
- Giorgio ScagliottiGSGiorgio Scagliotti
- Alessio SignoriAlessio Signori
Open Access
- 5 August 2021
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (12) , 3679-3692
Abstract
Debate is around the optimal immunization regimen for cancer vaccines since too intense vaccination schedules may exhaust reactive lymphocytes. GX301 is a telomerase-based cancer vaccine whose safety and immunological effects were tested in a phase I trial applying an eight administrations schedule. Main objective of this study was to comparatively analyse safety and immunological response to three GX301 regimens in metastatic castration-resistant prostate cancer patients with response/disease stability after docetaxel chemotherapy. This was a multicentre, randomized, parallel-group, open-label trial registered with EudraCT (2014-000095-26) and ClinicalTrials.gov (NCT02293707, 2014). Ninety-eight patients were randomized to receive either eight (regimen 1), four (regimen 2) or two (regimen 3) vaccine administrations. Sixty-three patients were assessable for the primary immunological end-point. Vaccine-specific immune responses were evaluated by intracellular staining for IFN, elispot and cytotoxic assay at 90 and 180 days from baseline. No major side effects were recorded. A 54% overall immune responder rate was observed with 95% of patients showing at least one vaccine-specific immune response. Rate of immunological responders and number of immunizations were proportionally related, suggesting superiority of regimens 1 and 2 over regimen 3. Overall survival did not differ among regimens in both immunological responders and non-responders and was inversely associated (P = 0.002) with increase in the number of circulating CD8 + T regulatory cells at 180 days. These data indicate that GX301 cancer vaccine is safe and immunogenic in metastatic castration-resistant prostate cancer patients. Schedules with high number of administrations should be preferred in future studies due to their better immunological outcome.Keywords
Funding Information
- Mediolanum Farmaceutici Spa
- Università degli Studi di Genova
This publication has 45 references indexed in Scilit:
- Comparative analysis of cancer vaccine settings for the selection of an effective protocol in miceJournal of Translational Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerCancer Immunology, Immunotherapy, 2012
- Harmonization of the intracellular cytokine staining assayCancer Immunology, Immunotherapy, 2012
- Unmasking the immune recognition of prostate cancer with CTLA4 blockadeNature Reviews Cancer, 2012
- Multiple VaccinationsThe Cancer Journal, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Cancer Immunology, Immunotherapy, 2007
- Specific Association of Human Telomerase Activity with Immortal Cells and CancerScience, 1994